LPC
AMPE

Loeb Partners Corp’s Ampio Pharmaceuticals Inc. AMPE Stock Holding History

Loeb Partners Corp’s Portfolio AMPE Stock Details AMPE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-17
Closed -$2K – 309
2018
Q4 		$2K Buy
+17
New +$2.61K ﹤0.01% 286

Other funds holding AMPE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
CC
Courier Capital Buffalo, New York $2B AUM 24.36% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Loeb Partners Corp's AMPE Position: Q1 2019 in Review

Loeb Partners Corp sold out of Ampio Pharmaceuticals Inc. (AMPE) in Q1 2019, closing a stake of 17 shares — an estimated $2K sold.

Loeb Partners Corp first reported a position in AMPE in Q4 2018 and held it in 1 quarter. The position peaked at $2K in Q4 2018. 84 funds tracked by Wall St. Rank hold AMPE as of Q1 2019.

  • Loeb Partners Corp reported no remaining Ampio Pharmaceuticals Inc. position as of Q1 2019 after selling out during the quarter.
  • Loeb Partners Corp sold 17 Ampio Pharmaceuticals Inc. shares in Q1 2019, an estimated $2K.
  • Loeb Partners Corp first reported a position in Ampio Pharmaceuticals Inc. in Q4 2018 and held it in 1 quarter.
  • Loeb Partners Corp's Ampio Pharmaceuticals Inc. position peaked at $2K in Q4 2018.
  • 84 funds tracked by Wall St. Rank held Ampio Pharmaceuticals Inc. as of Q1 2019.

Based on Loeb Partners Corp's 13F filing for Q1 2019, filed 14 May 2019.